E.g., 06/23/2021
E.g., 06/23/2021

VIDAS® D-Dimer Exclusion™ test from bioMérieux for reliable exclusion of pulmonary embolism and deep vein thrombosis

23 July, 2004

bioMérieux announces that its D-dimer assay, VIDAS D-Dimer Exclusion, is now cleared by the U.S. Food and Drug Administration (FDA) to exclude both pulmonary embolism (PE) and deep vein thrombosis (DVT) as a diagnosis in outpatients. VIDAS D-Dimer Exclusion is the first and only D-dimer assay to be cleared for exclusion of both conditions -- with no further testing -- when used in conjunction with a pre-test probability (PTP) assessment, in low-to-moderate probability outpatients.

NucliSens® easyMAG™ – new innovation from bioMérieux for nucleic acid extraction

07 June, 2004

A world leader in the field of in vitro diagnostics, bioMérieux announces the launch of its new automated sample preparation platform for the extraction of nucleic acid in molecular diagnostics assays. The NucliSens easyMAG system is the latest innovation in bioMérieux’s range of molecular diagnostic solutions

bioMérieux laboratories grant license to Eppendorf for One Step RT-PCR technology

13 May, 2004

Eppendorf AG, Germany, and bioMérieux, France, have concluded a non-exclusive licensing agreement for Eppendorf products using bioMérieux's exclusively controlled One Step RT-PCR technology.

VIDAS® D-Dimer Exclusion test from bioMérieux for reliable exclusion of venous thromboembolism

06 May, 2004

bioMérieux announces that following prospective management studies on its VIDAS D-Dimer test resulting in FDA approval and CE marking, the VIDAS D-Dimer New test has been renamed VIDAS D-Dimer Exclusion™. This name change will more accurately reflect the new intended use of the VIDAS D-Dimer Exclusion test, and also reinforce awareness of the significant role D-dimers can play in exclusion strategies for thromboembolic disease.

bioMérieux and South Africa, united in the fight against AIDS

04 May, 2004

A major player in the field of infectious disease, bioMérieux, and its exclusive distributor for South Africa, Omnimed, have just won a most important tender for the National Health Laboratory Services of South Africa as regards the fight against the AIDS virus.

BOOM® patent upheld in Europe

20 April, 2004

The European Patent Office’s Board of Appeal has found in favour of bioMérieux in the opposition to its European patent for the Boom technology.

bioMérieux invests in the future of emergency diagnostics

15 April, 2004

A world leader in the field of in vitro diagnostics, with over 40 years experience in infectious diseases, bioMérieux SA recently confirmed its commitment to the field of emergency diagnostics through its presence at the 25th International Symposium on Intensive Care and Emergency Medicine in Brussels on March 21–25, 2005.

NucliSens® miniMAG™, the first product from bioMérieux’s next generation nucleic acid extraction platform now available.

02 April, 2004

bioMérieux announces the introduction of NucliSens miniMAG and NucliSens Magnetic Extraction Reagents, two key components of the company’s next generation nucleic acid extraction technology.

U.S. FDA Premarket Notification 510(k) Clearance of Polycarbonate BacT/ALERT® Culture Bottles for Microbial QC Testing of Leukocyte-Reduced Single Units of Whole Blood Platelet Concentrates (WBPC)

26 March, 2004

bioMérieux announces U.S. FDA-CBER (1) Premarket Notification 510(k) clearance of the recently launched, innovative polycarbonate BacT/ALERT BPA and BacT/ALERT BPN culture bottles for microbial quality control testing of leukocyte-reduced single units of whole blood platelet concentrates (WBPC).

bioMérieux launches VITEK® 2 Compact, its new solution for rapid identification of micro-organisms

10 February, 2004

bioMérieux, a major player in the field of microbiological controls for the pharmaceutical and agri-food industries, introduces VITEK®2 Compact, the newest addition to its range of automated identification systems.

Pioneering diagnostics